Optomed Oyj in brief
Optomed Oyj is a listed company in the Healthcare sector, based in Finland. Its last known market value was $73 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $19 M and a net loss of $7 M. Its shares trade under the symbol OPTOMED.HE (Nasdaq Nordic).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Optomed Oyj timeline
- 2004
- 🏁· approximateIncorporated as Optomed Oyj
- 2019
- •Legal Entity Identifier issuedLEI 7437009IVYWGEE4S7B77 registered.
Events of Optomed Oyj from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Finland: #100 (Jan 2022) · #112 (Dec 2022) · #113 (Jul 2023) · #106 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -38.9%
- Operating margin
- -35.3%
- Return on equity
- -26.5%
- Liabilities / assets
- 24.9%
- Revenue growth
- +18.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $19M | +18.4% | $-7M | $-7M | -38.9% |
| Dec 2024 | $16M | — | $-6M | $-6M | -36.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-3M | $1M | $-3M | — | — |
| Dec 2024 | $-2M | $0M | $-2M | — | — |
Annual results
- Revenue
- $19 M
- Operating income
- $-7 M
- Net income
- $-7 M
For year ending December-2025 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $38 M
- Total liabilities
- $9 M
- Total equity
- $28 M
As of December-2025
Mutual funds holding Optomed Oyj#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇸🇪 Handelsbanken Norden Index CriteriaHandelsbanken Fonder AB | 381,418 | $1 M | — | 0.02% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Optomed Oyj scorecard#
Passes 1 of the 4 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 1
- ✓Revenue grew in the newest year18.4%Revenue up 18.4% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-35.3%-35.3% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%-28.4%-28.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (esef), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Optomed Oyj's statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -35.3% | -7.7% | |
| Net margin | -38.9% | -8.1% | |
| Return on equity | -28.4% | -36.9% | |
| Revenue growth | 18.4% | 10.2% | |
| Free cash flow margin | -17.8% | -1.3% |
2of 5on the Piotroski tests of financial strength
- Net loss of $7 million.
- Free cash flow was negative: -$3 million.
Optomed Oyj: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 17,096+13.7%100% | 15,040−0.4%100% | 15,100+3.0%100% | 14,660−1.3%100% | 14,850+14.1%100% | 13,011−13.1%100% | 14,977—100% | |
| Operating income | −6,042—−35.3% | −5,957—−39.6% | −3,974—−26.3% | −5,097—−34.8% | −4,780—−32.2% | −2,906—−22.3% | −2,596—−17.3% | |
| Interest and finance income | 580−52.3%3.4% | 1,217+154%8.1% | 479−15.8%3.2% | 569−20.4%3.9% | 715+58.2%4.8% | 452+5550%3.5% | 8.0—0.1% | |
| Interest expense and finance costs | 1,256+61.9%7.3% | 776−24.2%5.2% | 1,0240.0%6.8% | 1,024+289%7.0% | 263−66.9%1.8% | 794+118%6.1% | 365—2.4% | |
| Income before tax | −6,718—−39.3% | −5,516—−36.7% | −4,519—−29.9% | −5,551—−37.9% | −4,327—−29.1% | −3,247—−25.0% | −2,952—−19.7% | |
| Income tax | −77—−0.5% | −66—−0.4% | −79—−0.5% | −79—−0.5% | −78—−0.5% | −70—−0.5% | −77—−0.5% | |
| Net income including minority interests | −6,640—−38.8% | −5,450—−36.2% | −4,441—−29.4% | −5,472—−37.3% | −4,249—−28.6% | −3,177—−24.4% | −2,875—−19.2% | |
| Net income attributable to shareholders | −6,640—−38.8% | −5,450—−36.2% | −4,441—−29.4% | −5,472—−37.3% | −4,249—−28.6% | −3,177—−24.4% | −2,875—−19.2% | |
| Earnings per share, basic | -0.34—— | -0.29—— | -0.27—— | -0.37—— | -0.32—— | -0.24—— | -0.32—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 9,909−5.3%31.0% | 10,467+47.0%32.9% | 7,118−16.5%24.5% | 8,524+25.3%27.2% | 6,804−35.9%23.5% | 10,608−43.8%34.1% | 18,866—47.6% | |
| Receivables | 2,756+14.3%8.6% | 2,411−6.7%7.6% | 2,583−27.4%8.9% | 3,556−2.8%11.4% | 3,658+38.6%12.6% | 2,639−8.9%8.5% | 2,897—7.3% | |
| Inventory | 2,382+21.5%7.5% | 1,961−30.5%6.2% | 2,820−5.9%9.7% | 2,998+2.1%9.6% | 2,936+15.6%10.1% | 2,539+2.9%8.2% | 2,468—6.2% | |
| Current assets | 15,765+0.4%49.3% | 15,695+19.6%49.4% | 13,128−18.4%45.1% | 16,090+12.0%51.4% | 14,371−14.4%49.6% | 16,784−34.1%54.0% | 25,459—64.3% | |
| Property, plant and equipment | 894+37.1%2.8% | 652−8.2%2.1% | 710−16.7%2.4% | 852+96.8%2.7% | 433+20.6%1.5% | 359−11.6%1.2% | 406—1.0% | |
| Right-of-use (leased) assets | 1,212−16.8%3.8% | 1,456−1.1%4.6% | 1,472+1.7%5.1% | 1,448+20.2%4.6% | 1,205+3.4%4.2% | 1,165+8.4%3.7% | 1,075—2.7% | |
| Goodwill | 4,2560.0%13.3% | 4,2560.0%13.4% | 4,2560.0%14.6% | 4,2560.0%13.6% | 4,2560.0%14.7% | 4,2560.0%13.7% | 4,256—10.7% | |
| Non-current assets | 16,208+0.8%50.7% | 16,085+0.8%50.6% | 15,951+4.9%54.9% | 15,210+4.0%48.6% | 14,626+2.4%50.4% | 14,289+1.0%46.0% | 14,151—35.7% | |
| Total assets | 31,973+0.6%100% | 31,781+9.3%100% | 29,079−7.1%100% | 31,300+7.9%100% | 28,998−6.7%100% | 31,073−21.6%100% | 39,611—100% | |
| Current liabilities | 6,593+18.1%20.6% | 5,583+10.5%17.6% | 5,052−3.3%17.4% | 5,227+6.4%16.7% | 4,912+40.8%16.9% | 3,489−53.8%11.2% | 7,557—19.1% | |
| Long-term debt | 0−100%0.0% | 790−52.2%2.5% | 1,651−51.2%5.7% | 3,380−11.4%10.8% | 3,813+8.3%13.1% | 3,520−31.0%11.3% | 5,104—12.9% | |
| Lease liabilities (non-current) | 835−17.9%2.6% | 1,017+2.6%3.2% | 991−6.3%3.4% | 1,058+29.3%3.4% | 818+4.6%2.8% | 782+11.9%2.5% | 699—1.8% | |
| Non-current liabilities | 1,363−46.8%4.3% | 2,561−30.1%8.1% | 3,665−36.0%12.6% | 5,731−18.5%18.3% | 7,034−6.4%24.3% | 7,512−20.2%24.2% | 9,416—23.8% | |
| Total liabilities | 7,956−2.3%24.9% | 8,144−6.6%25.6% | 8,718−20.4%30.0% | 10,957−8.3%35.0% | 11,946+8.6%41.2% | 11,001−35.2%35.4% | 16,973—42.8% | |
| Total equity | 24,016+1.6%75.1% | 23,637+16.1%74.4% | 20,361+0.1%70.0% | 20,342+19.3%65.0% | 17,052−15.1%58.8% | 20,073−11.3%64.6% | 22,637—57.1% | |
| Total liabilities and equity | 31,973+0.6%100% | 31,781+9.3%100% | 29,079−7.1%100% | 31,300+7.9%100% | 28,998−6.7%100% | 31,073−21.6%100% | 39,611—100% | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | — | — | — | — | — | — | 2,261—15.1% | |
| Cash from operating activities | −2,482—−14.5% | −1,596—−10.6% | −615—−4.1% | −2,370—−16.2% | −2,940—−19.8% | −2,801−1840%−21.5% | 161—1.1% | |
| Capital expenditure | −561—−3.3% | −275—−1.8% | −213—−1.4% | −780—−5.3% | −462—−3.1% | −268—−2.1% | −260—−1.7% | |
| Intangible assets bought | −1,796—−10.5% | −1,843—−12.3% | −2,199—−14.6% | −2,249—−15.3% | −2,112—−14.2% | −1,553—−11.9% | −1,175—−7.8% | |
| Cash from investing activities | −2,357—−13.8% | −2,118—−14.1% | −2,412—−16.0% | −3,029—−20.7% | −2,574—−17.3% | −1,820—−14.0% | −1,434—−9.6% | |
| Debt issued | — | — | — | — | 1,366—9.2% | −167−195%−1.3% | 176—1.2% | |
| Debt repaid | −863—−5.0% | −1,053—−7.0% | −1,921—−12.7% | −912—−6.2% | −327—−2.2% | −3,233—−24.8% | −460—−3.1% | |
| Shares issued | 5,984−34.8%35.0% | 9,182+113%61.1% | 4,310−52.2%28.5% | 9,012+791%61.5% | 1,012+1000%6.8% | 92−99.6%0.7% | 23,000—154% | |
| Cash from financing activities | 4,186−40.9%24.5% | 7,081+340%47.1% | 1,609−77.0%10.7% | 7,003+328%47.8% | 1,637—11.0% | −3,698−120%−28.4% | 18,123—121% | |
| Exchange-rate effect on cash | 95—0.6% | −19−246%−0.1% | 13−88.7%0.1% | 115+57.5%0.8% | 73+19.7%0.5% | 61+259%0.5% | 17—0.1% | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How Optomed Oyj compares in Healthcare
- Revenue$19 M · higher than 26% of 1,795
- Net margin-38.9% · higher than 25% of 1,485
- Revenue growth18.4% · higher than 67% of 1,003
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Optomed Oyj🇫🇮 | $73 M | — | -38.9% | +18.4% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- UnitedHealth Group Incorporated$367.7 B
- Merck & Co., Inc.$359.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 15, 2026
Figures from Official annual report (ESEF), value.today research, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Optomed Oyj? Verify and update this profile — free
Show Optomed Oyj's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.